YD BioYDES +0.87%12 FCF Yield % is -4.91 as of Jul. 01, 2026. GuruFocus rates YDES with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,414 Biotechnology companies, YD Bio ranks better than 62.45% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, YD Bio's Trailing 12-Month Free Cash Flow is $-8.04 Mil, and Market Cap is $163.62 Mil. Therefore, YD Bio's FCF Yield % for today is -4.91%.
The historical rank and industry rank for YD Bio's FCF Yield % or its related term are showing as below:
YDES'
s FCF Yield % Range Over the Past 10 Years
Min: -5.26 Med: -1.06 Max: -0.26
Current: -4.91
During the past 3 years, the highest FCF Yield % of YD Bio was -0.26%. The lowest was -5.26%. And the median was -1.06%.
YDES's FCF Yield % is ranked better than 62.45% of 1414
companies
in the Biotechnology industry
Industry Median: -9.46
vs YDES: -4.91
YD Bio's FCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.
YD Bio FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
YD Bio FCF Yield % Related Terms
YD Bio FCF Yield % Historical Data
* Premium members only.
The historical data trend for YD Bio's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
YD Bio FCF Yield % Chart
YD Bio Annual Data
Trend
Dec23
Dec24
Dec25
FCF Yield %
0.00
0.00
-0.93
YD Bio Semi-Annual Data
Dec24
Jun25
Dec25
FCF Yield %
0.00
0.00
0.00
YDES vs CRBU, ABOS, PRQR: FCF Yield % Comparison
For the Biotechnology subindustry, YD Bio's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
YD Bio FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, YD Bio's FCF Yield % distribution charts can be found below:
* The bar in red indicates where YD Bio's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
YD Bio (YDES) has a FCF Yield % of -4.91 as of Jul. 01, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on YD Bio and its competitors. According to the industry distribution chart, YD Bio ranks #531 out of 1414 companies in the Biotechnology industry, placing it in the top 37.6%.
Is YD Bio's FCF Yield % too high?
YD Bio's current FCF Yield % is -4.91. Based on the distribution chart, YD Bio ranks #531 out of 1414 companies in the Biotechnology industry, which is above the industry midpoint. Overall, YD Bio has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does YD Bio's FCF Yield % compare to CRBU and ABOS?
According to the Biotechnology industry distribution chart, YD Bio ranks #531 out of 1414 companies for FCF Yield %. This puts YD Bio in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on YD Bio and its competitors. YD Bio's current FCF Yield % is -4.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is YD Bio stock overvalued right now?
YD Bio (YDES) has a current FCF Yield % of -4.91. The current FCF Yield % is -4.91. YD Bio's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For YD Bio (YDES), the current FCF Yield % is -4.91 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.
12GF Score
Get the complete analysis for YDES
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
YDES has been successfully added to your 